Applications of Real-World Data and Real-World Evidence in Decision-Making in Asia Pacific

Speaker(s)

Moderator: Larry Z Liu, MD, PhD, Center for Observational and Real-world Evidence (CORE), Merck & Co., Inc., Princeton Jct, NJ, USA
Speakers: Viva Ma, PhD, MBA, Becton, Dickinson and Company, Singapore, Singapore; Jianwei Xuan, PhD, Health Economic Research Institute, Sun Yat-sen University, Guangzhou, China

Presentation Documents

The applications of Real-World Data (RWD) and Real-World Evidence (RWE) in healthcare have advanced significantly in Asia Pacific, as in other parts of the world. In particular, China and Japan, the second and third largest pharmaceutical markets in the world, have made substantial policy changes in promoting the use of RWD and RWE in regulatory approvals, reimbursement and clinical decision making. RWE not only provides information on the clinical outcomes, but also on operational outcomes and economic outcomes. RWE can help reduce the uncertainties of adopting new technologies from industry, payer, and policy maker’s perspectives, as it is assessed based on actual clinical practice on much broader patient population. It is critical to promote and to accelerate the adoption of RWE in more health systems to benefit patient access and towards improved outcome. The objective of this forum is to provide the most recent update on the use of real-world data (RWD) and real-world evidence (RWE) in regulatory, reimbursement, and clinical decision making in Asia Pacific. In this session, Dr. Larry Liu will provide a comprehensive update of the use of RWD and RWE for regulatory and clinical decision making in China and Japan with specific case examples. Dr. Viva Ma will focus on the applications of RWE in medical device market access across the region. Dr. Jianwei Xuan will present the application of RWE in reimbursement decisions as well as hospital payment reform in China.

Code

117

Topic

Health Policy & Regulatory